Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism

Area of Science:

• Immunology
• Cancer Biology
• Molecular Medicine

Background:

• Immunotherapy with checkpoint inhibitors benefits only a subset of cancer patients.
• Tumoral immune resistance mechanisms include T-cell dysfunction and apoptosis.
• Death receptors (Fas, DR3, DR4, DR5, TNFR1) and their ligands induce apoptosis.

Purpose of the Study:

• To review the immunomodulatory roles of death receptors in the tumor microenvironment.
• To focus on the Fas/FasL pathway and its impact on T-cell apoptosis and anti-tumor immunity.
• To explore the potential of targeting the Fas/FasL pathway to enhance cancer immunotherapy efficacy.

Main Methods:

• Review of existing literature on death receptors, apoptosis, and cancer immunotherapy.
• Analysis of the role of Fas and Fas ligand (FasL) in T-cell-mediated immune responses.
• Examination of how tumor microenvironment cells contribute to FasL-mediated T-cell apoptosis.

Main Results:

• Fas-mediated T-cell apoptosis, known as activation-induced cell death, acts as an immune checkpoint.
• Tumor microenvironment cells (endothelial, myeloid-derived suppressor cells) can express FasL, inducing T-cell apoptosis.
• This FasL-mediated T-cell killing contributes to "cold" tumors and lack of tumor-infiltrating lymphocytes (TIL).

Conclusions:

• Interfering with the Fas/FasL pathway in the tumor microenvironment is a potential strategy to overcome immunotherapy resistance.
• Targeting Fas-mediated apoptosis could enhance anti-tumor immunity and improve clinical outcomes for non-responding patients.
• Understanding Fas-FasL interactions is crucial for developing novel cancer immunotherapies.